A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases

DePalo, DK; Dugan, MM; Naqvi, SMH; Ollila, DW; Hieken, TJ; Block, MS; van Houdt, WJ; Wouters, Mwjm; Reijers, SJM; Asher, N; Broman, KK; Duncan, Z; Anderson, M; Gyorki, DE; Snow, H; Held, J; Farma, JM; Vetto, JT; Hui, JYC; Kolbow, M; Saw, RPM; Lo, SN; Long, GV; Thompson, JF; Kim, Y; Karapetyan, L; Ny, L; van Akkooi, ACJ; Olofsson Bagge, R; Zager, JS

Author(s): DePalo, DK; Dugan, MM; Naqvi, SMH; Ollila, DW; Hieken, TJ; Block, MS; van Houdt, WJ; Wouters, Mwjm; Reijers, SJM; Asher, N; Broman, KK; Duncan, Z; Anderson, M; Gyorki, DE; Snow, H; Held, J; Farma, JM; Vetto, JT; Hui, JYC; Kolbow, M; Saw, RPM; Lo, SN; Long, GV; Thompson, JF; Kim, Y; Karapetyan, L; Ny, L; van Akkooi, ACJ; Olofsson Bagge, R; Zager, JS;
Details: Publication Year 2025-01-01,Volume 131,Issue #1,Page e35636
Journal Title: Cancer
Publication Type: Research article
Abstract: BACKGROUND: Isolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in-transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene laherparepvec [TVEC]) introduced several different management options. This study compares first-line ILI/ILP, ICI, and TVEC. METHODS: Retrospective review from 12 international institutions included patients treated from 1990 to 2022 with first-line ILI/ILP, ICI, or TVEC for unresectable melanoma ITM. RESULTS: A total of 551 patients were treated, with ILI/ILP (n = 356), ICI (n = 125), and TVEC (n = 70) with median follow-up of 5.5 years. Tumor burden was highest with ILI/ILP and lowest with TVEC (p = .002). Breslow thickness was lowest with TVEC (p = .007). TVEC was mostly used in stage IIIB disease versus IIIC for ILI/ILP and ICI (p = .01). Using ICI as the reference category, TVEC had the highest odds of a complete response (CR) (odds ratio, 1.96; p = .029) and a longer local progression-free survival (PFS) (hazard ratio [HR], 0.40; p = .003). ILI/ILP had shorter local PFS (HR, 1.72; p = .012), PFS (HR, 1.79; p < .001), distant metastasis-free survival (DMFS) (HR, 1.75; p = .014), overall survival (HR, 1.82; p = .009), and melanoma-specific survival (HR, 2.29; p = .004). Stage IIIB disease had longer DMFS (HR, 0.24; p < .001) compared to IIIC/D. CONCLUSIONS: TVEC as first-line therapy for unresectable melanoma ITM was associated with superior CR rates and local PFS. Notably, TVEC was used in patients with a lower Breslow thickness, disease stage, and tumor burden. Therefore, when compared to ILI/ILP and ICI, TVEC should be considered as first-line therapy for unresectable stage IIIB melanoma ITM with minimal tumor burden and lower Breslow thickness.
Publisher: Wiley
Keywords: Humans; *Melanoma/drug therapy/pathology/mortality; *Immune Checkpoint Inhibitors/administration & dosage/therapeutic use; Male; Female; Middle Aged; Aged; Retrospective Studies; Adult; Aged, 80 and over; Skin Neoplasms/drug therapy/pathology/mortality; Extremities/pathology; Chemotherapy, Cancer, Regional Perfusion/methods; Neoplasm Metastasis; Biological Products; Herpesvirus 1, Human; immune checkpoint inhibitors; intralesional therapy; in‐transit metastasis; isolated limb infusion; isolated limb perfusion; metastatic melanoma; regional chemotherapy; talimogene laherparepvec
Department(s): Surgical Oncology
Publisher's Version: https://doi.org/10.1002/cncr.35636
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-01-21 12:27:19

Last Modified: 2025-01-21 12:27:42